Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWChelidonic acid is a pyran that has been found in C. majus and has diverse biological activities.1,2,3 It inhibits rat brain glutamate decarboxylase (Ki = 1.2 μM).2 Chelidonic acid (20 mg/kg per day) reduces serum IL-6 and TNF-α levels, colonic COX-2 and prostaglandin E2 (PGE2; Item No. 14010) levels, and the disease activity index score in a mouse model of ulcerative colitis induced by dextran sulfate sodium (DSS; Item No. 23250).1 It inhibits ovalbumin challenge-induced decreases in spleen IFN-γ levels and increases in serum, spleen, and nasal mucosa IgE levels, spleen IL-4 levels, and nasal mucosa eosinophil and mast cell infiltration in a mouse model of ovalbumin-sensitized allergic rhinitis when administered at a dose of 2 mg/kg.3
WARNING This product is not for human or veterinary use.
1. The therapeutic effect of chelidonic acid on ulcerative colitis. Biol. Pharm. Bull. 35(5), 666-671 (2012).
2. Chelidonic acid and other conformationally restricted substrate analogues as inhibitors of rat brain glutamate decarboxylase. Biochem. Pharmacol. 34(23), 4145-4150 (1985).
3. Beneficial effects of chelidonic acid on a model of allergic rhinitis. Int. Immunopharmacol. 11(1), 39-45 (2011).